Cannell & Co. Regeneron Pharmaceuticals, Inc. Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
A detailed history of Cannell & Co. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Cannell & Co. holds 10,742 shares of REGN stock, worth $5.78 Million. This represents 0.31% of its overall portfolio holdings.
Number of Shares
10,742
Previous 10,917
1.6%
Holding current value
$5.78 Million
Previous $8.98 Million
5.01%
% of portfolio
0.31%
Previous 0.32%
Shares
24 transactions
Others Institutions Holding REGN
# of Institutions
1,472Shares Held
85.8MCall Options Held
1.39MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA9.41MShares$5.06 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.55 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.04 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.58 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$2.15 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $57.7B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...